Search Result

Results for "

pharmacokinetic parameters

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (1) Bacterial (1) Calcium Channel (1) CD3 (1) Endogenous Metabolite (1) HSP (1) IFNAR (1) Interleukin Related (1) Na+/K+ ATPase (1) Parasite (1) PARP (1) PGE synthase (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (1) Sodium Channel (2) STING (1)
By Research Areas:	Cancer (3) Infection (2) Inflammation/Immunology (3) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

HY-123367

Rubraxanthone	Platelet-activating Factor Receptor (PAFR)	Others
Rubraxanthone is a compound with multiple biological activities. Its pharmacokinetic parameters were determined in mice and it showed a certain concentration variation pattern in plasma after oral administration.

HY-118683

KR-31378	Potassium Channel	Others
KR-31378 is a neuroprotectant with dose-dependent pharmacokinetic properties and relevant activity in rats. After intravenous and oral administration of KR-31378 in rats, its pharmacokinetic parameters showed dose-dependent changes, such as decreased clearance with increasing doses, good oral absorption, and comparable AUCs for intravenous and oral administration at different doses.

HY-170895

Hsp90-IN-38	HSP Na+/K+ ATPase	Cancer
Hsp90-IN-38 (compound 20m) is a HSP90 (heat shock protein) inhibitor. Hsp90-IN-38 exhibits strong HSP90 binding affinity with a K_d of 87 nM. Hsp90-IN-38 inhibits ATPase with an IC₅₀ of 0.13 μM. Hsp90-IN-38 inhibits HCT116, MCF-7, SKBr3, K562 and A549 cells with IC₅₀s of 0.187, 0.072, 0.105, 0.403 and 031 μM, respectively .

HY-A0148B

(-)-Halofantrine (-)-SKF-102886 free base; (-)-WR-171669	Parasite	Infection
(-)-Halofantrine ((-)-SKF-102886 free base; (-)-WR-171669) is an inhibitor of the malignant malaria parasite (P. falciparum) and targets multidrug-resistant P. falciparum. The pharmacokinetic parameters of (-)-Halofantrine in rats vary depending on the route of administration, distinguishing it from other isomers .

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent PARP-2 inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-117831

NSC-79887	Bacterial Antibiotic Endogenous Metabolite	Infection
NSC-79887 is a nucleoside hydrolase (NH) inhibitor with activity against Bacillus anthracis. NSC-79887 is considered a good candidate inhibitor of nucleoside hydrolases for biological testing and further development. The pharmacokinetic (ADMET) prediction of NSC-79887 showed that all physicochemical parameters were within the acceptable range for human use .

HY-146662

HPGDS inhibitor 3	PGE synthase	Inflammation/Immunology
HPGDS inhibitor 3 is an orally active and highly potent peripherally restricted hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC₅₀ value of 9.4 nM and EC₅₀ of 42 nM, respectively. HPGDS inhibitor 3 exhibits good selectivity, good pharmacokinetic parameters in mouse, rat, and dog, and no CNS toxicity. HPGDS inhibitor 3 has anti-inflammatory activity .

HY-168952

GHN105	STING IFNAR Interleukin Related	Inflammation/Immunology
GHN105 is an orally active inhibitor for STING that inhibits STING-dependent IFN-β secretion in THP-1 human monocytes with an IC₅₀ of 4.4 μM. GHN105 reduces the IFN-β, IL-6 and CXCL10 levels in serum, and alleviates colitis in DSS (HY-116282)-induced acute colitis mouse model. GHN105 exhibits good pharmacokinetic parameters in mice with an oral bioavailability of 43% and a half-life of 1.1 hours .

HY-128794

PF-05150122	Sodium Channel	Neurological Disease
PF-05150122 is a novel potent and selective human Nav1.7 channel blocker with the activity of inhibiting human pain signaling. PF-05150122 exhibited favorable biopharmacokinetic parameters in microdose studies, providing a basis for exploring its application in acute or chronic pain inhibition. The pharmacokinetic model of PF-05150122 predicted that at the corresponding oral dose, it could effectively reduce the 50% inhibitory concentration (IC50) of Nav1.7, demonstrating its inhibitory potential .

HY-121535

Levosemotiadil	Sodium Channel Calcium Channel	Others
Levosemotiadil, an S-isomer of semotiadil, exhibits stronger binding affinity to human serum albumin (HSA) compared to its R-isomer counterpart. This study utilized high-performance frontal analysis (HPFA) to demonstrate that levosemotiadil binds approximately three times more strongly to HSA than semotiadil. The binding parameters were evaluated using Scatchard analysis, revealing specific interactions with the diazepam binding site on HSA. The presence of diazepam decreased the binding affinity of both enantiomers, while warfarin did not alter their binding characteristics. These findings highlight levosemotiadil's potential as a Ca- and Na-channel blocker with significant binding preferences for HSA, crucial for understanding its pharmacokinetics and therapeutic effects .

Cat. No.	Product Name

HY-L042

Glycoside Compound Library	791 compounds
Glycosides are compounds in which a sugar group is bonded through its anomeric carbon to another group via a glycosidic bond. Many biologically active compounds are glycosides. Glycosides comprise several important classes of compounds such as hormones, sweeteners, alkaloids, flavonoids, antibiotics, etc. The glycosidic residue can be crucial for their activity or can only improve pharmacokinetic parameters. Glycosides, which exhibit anti-inflammatory, anti-infection, anti-cancer and anti-oxidative properties, play numerous important roles in living organisms, such as streptomycin, as an aminoglycoside antibiotic, has anti-infection activity. Anthracyclines possess good antibacterial and anti-cancer activities. MCE Glycoside Compound Library contains a unique collection of 791 glycoside compounds and is a useful tool to discovery glycoside drugs.

Glycoside Compound Library

791 compounds

Glycosides are compounds in which a sugar group is bonded through its anomeric carbon to another group via a glycosidic bond. Many biologically active compounds are glycosides. Glycosides comprise several important classes of compounds such as hormones, sweeteners, alkaloids, flavonoids, antibiotics, etc. The glycosidic residue can be crucial for their activity or can only improve pharmacokinetic parameters. Glycosides, which exhibit anti-inflammatory, anti-infection, anti-cancer and anti-oxidative properties, play numerous important roles in living organisms, such as streptomycin, as an aminoglycoside antibiotic, has anti-infection activity. Anthracyclines possess good antibacterial and anti-cancer activities.

MCE Glycoside Compound Library contains a unique collection of 791 glycoside compounds and is a useful tool to discovery glycoside drugs.

Cat. No.	Product Name	Target	Research Area

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.